方法：回顾分析急性CSC患者48例48眼的临床资料，其中24例患者口服四苓散(治疗组)，另外24例患者不接受治疗(对照组)。获取和比较两组患者基线值和随访1，3mo的临床数据，包括最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)及视网膜下液最大高度(SRF)。

结果：治疗组1mo时的BCVA与基线相比无统计学差异(P>0.05)，3mo时的BCVA比基线值有改善(P<0.05)，3mo较1mo时的BCVA有所好转(P<0.05)； 而对照组的BCVA在3mo内无明显变化(均P>0.05)。两组BCVA在基线，1，3mo时均无明显差异(P>0.05)。治疗组1，3mo的CMT和SRF均较基线值降低，且差异均具有统计学意义(P<0.05)，3mo较1mo时的CMT和SRF也明显降低(均P<0.05)。对照组1mo时的CMT和SRF与基线相比，变化无统计学差异(均P>0.05)，3mo的CMT和SRF较基线明显降低，差异有统计学意义(均P<0.05)，3mo较1mo时的CMT和SRF也明显降低(均P<0.05)。1，3mo时治疗组的CMT和SRF均较对照组明显降低，且差异有统计学意义(均P<0.05)。

结论：口服四苓散具有治疗急性CSC的潜能，但在其提高视功能、缩短病程、减少复发等方面的作用仍需进一步研究。

METHODS: We retrospectively analyzed the clinical data of 48 patients(48 eyes)with CSC, among whom 24 were given oral Si Ling San(as treatment group)and the other 24 did not receive any treatment(control group). The baseline and 1 or 3mo follow-up data for the best corrected visual acuity(BCVA), central macular thickness(CMT)and maximum height of subretinal fluid(SRF)were collected and then compared between the two groups.

RESULTS: BCVA of the treatment group was not statistically different from the baseline level at 1mo(P>0.05), but it was significantly improved at 3mo(P<0.05). BCVA was better at 3mo than that at 1mo(P<0.05). In the control group, however, no significant improvement of BCVA was found at 1 or 3mo compared with baseline(both P>0.05). The BCVA of the two groups was not significantly different at baseline and 1 and 3mo follow-up(all P>0.05). In the treatment group CMT and SRF at 1 and 3mo were significantly lower than baseline(both P<0.05). CMT and SRF at 3mo were significantly lower than that at 1 month(both P<0.05). In the control group, CMT and SRF at 1mo were not different from baseline level(both P>0.05), while they were significantly decreased at 3mo follow-up(both P<0.05). CMT and SRF at 3mo were significantly lower than that at 1mo(both P<0.05). In addition, CMT and SRF of the treatment group at both 1 and 3mo were statistically lower than that of the control group(all P<0.05).

CONCLUSION: This study preliminary suggest that oral Si Ling San has the potential to treat acute CSC. But further trials are warranted to study its role in improving the visual function, shortening the duration and reducing the recurrence of CSC.